Your browser is no longer supported. Please, upgrade your browser.
NVGN Novogen Limited daily Stock Chart
Novogen Limited
Index- P/E- EPS (ttm)-4.03 Insider Own28.80% Shs Outstand5.08M Perf Week-1.57%
Market Cap15.65M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.75M Perf Month-3.42%
Income-8.50M PEG- EPS next Q- Inst Own1.60% Short Float0.06% Perf Quarter-14.42%
Sales0.20M P/S78.26 EPS this Y79.80% Inst Trans3.83% Short Ratio0.31 Perf Half Y-46.88%
Book/sh4.20 P/B0.73 EPS next Y- ROA-26.80% Target Price16.00 Perf Year-59.88%
Cash/sh- P/C- EPS next 5Y- ROE-32.20% 52W Range2.61 - 8.40 Perf YTD-47.42%
Dividend- P/FCF- EPS past 5Y-20.10% ROI-72.80% 52W High-63.32% Beta0.12
Dividend %- Quick Ratio3.60 Sales past 5Y-29.70% Gross Margin- 52W Low18.04% ATR0.12
Employees12 Current Ratio3.60 Sales Q/Q1679.70% Oper. Margin- RSI (14)48.78 Volatility2.78% 2.58%
OptionableNo Debt/Eq0.00 EPS Q/Q79.50% Profit Margin- Rel Volume0.35 Prev Close3.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume8.62K Price3.08
Recom2.00 SMA20-0.76% SMA50-2.63% SMA200-34.22% Volume3,000 Change-0.61%
Jul-31-15Reiterated H.C. Wainwright Buy $8.50 → $5
Jul-01-15Initiated H.C. Wainwright Buy $8.50
Sep-11-17 07:45AM  Edison Issues ADR Update on Novogen (NVGN) ACCESSWIRE
Aug-30-17 06:00PM  Australian cancer specialists may hold key to next advancement in ovarian cancer treatment PR Newswire
Aug-22-17 06:00AM  GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 PR Newswire
12:06AM  GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 PR Newswire
Aug-14-17 06:00AM  Board Review of Business Operations and Governance PR Newswire
Aug-13-17 11:02PM  Board Review of Business Operations and Governance PR Newswire
Aug-07-17 07:00AM  Progress Update on Cantrixil(TM) (TRXE-002-1) Development PR Newswire
Aug-06-17 11:03PM  Progress Update on Cantrixil(TM) (TRXE-002-1) Development PR Newswire
Apr-04-17 11:45AM  Democrats found a way to speak Trump's language in pharma debate Yahoo Finance
Mar-27-17 06:11AM  Novogen Receives $4.4M R&D Tax Rebate Benzinga
Mar-10-17 06:00AM  Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure PR Newswire
Mar-09-17 08:21PM  Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure PR Newswire
Mar-06-17 05:54AM  Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program PR Newswire -6.86%
04:32AM  Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program PR Newswire
Nov-03-16 01:04PM  NOVOGEN LTD Financials
Oct-30-16 11:40PM  Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma PR Newswire
11:35PM  Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma PR Newswire
08:00PM  Novogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M Upfront , Plus Milestones Benzinga
07:49PM  Novogen Acquires Privately-held Glioblast for AU$2.1M in Cash, Stock, Plus Milestones Other
Sep-14-16 12:07AM  Conversion of Convertible Notes Other -9.05%
Sep-12-16 01:56AM  Novogen secures key US drug study approval AAP +6.48%
Sep-11-16 10:59PM  US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer PR Newswire
07:30PM  Novogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer Benzinga
Aug-11-16 07:00AM  Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer PR Newswire +9.54%
01:59AM  Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer PR Newswire
Jun-14-16 07:00AM  Novogen Patent Covering Anisina(TM) Has Proceeded to Grant PR Newswire
Jun-13-16 08:30PM  Novogen Patent Covering Anisina(TM) Has Proceeded to Grant Other
May-02-16 07:00AM  Novogen Provides Update On Development Of Cantrixil PR Newswire
May-01-16 10:43PM  Novogen Provides Update On Development Of Cantrixil Other
Mar-16-16 10:02PM  Novogen Receives R&D Tax Incentive Cash Refund Other
Feb-19-16 12:11AM  Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant PR Newswire
Feb-05-16 02:19AM  Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed PR Newswire
Jan-31-16 04:39PM  Letter to Shareholders from CEO James Garner Other
Dec-09-15 07:56PM  Novogen appoints new CEO AAP
04:59PM  Novogen Appoints Dr James Garner as Chief Executive Officer PR Newswire
Nov-23-15 07:38PM  Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial PR Newswire
Nov-11-15 07:04PM  Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia PR Newswire
Nov-10-15 05:34PM  Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina PR Newswire
Sep-30-15 06:18AM  Novogen Applies for Long-Term Options Listing on ASX Benzinga
Sep-29-15 10:52PM  Novogen Applies for Long-term Options Listing PR Newswire
Aug-31-15 02:20PM  Novogen (NVGN) Conducts Scientific Review of R&D Program
Aug-30-15 07:00PM  Novogen Announces The Outcome Of A Comprehensive Science Review PR Newswire
Jul-30-15 02:26AM  Novogen to review pre-clinical programs AAP
Jul-29-15 07:54PM  Newly Appointed Acting CEO Outlines Immediate Plans for Novogen PR Newswire
07:22PM  Novogen to review its pre-clinical trials AAP
Jul-22-15 12:56AM  Former CEO: Novogen in sound position AAP
Jul-21-15 10:34PM  Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board PR Newswire
08:16PM  Novogen shares tumble AAP
08:08PM  Novogen chief executive resigns AAP
Jul-16-15 03:37AM  Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma PR Newswire
Jul-14-15 02:45AM  Novogen shares soar on cancer drug study AAP
Jul-13-15 08:31PM  Novogen leaps on cancer drug study news AAP
04:30PM  Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer PR Newswire
Jul-01-15 09:06AM  H.C. Wainwright: Time To Buy Novogen Benzinga
07:06AM  Coverage initiated on Novogen by H.C. Wainwright
Jun-23-15 10:54PM  Novogen Announces the Chairman's Address at the Company's General Meeting PR Newswire
08:00PM  Anisina on Track to Enter Clinic in 2016 PR Newswire
Jun-16-15 08:30AM Publishes New SNNLive Video Interview With Novogen Limited Marketwired
Jun-12-15 12:15AM  Novogen to Present at Bio International Convention Philadelphia 2015 PR Newswire
Jun-05-15 02:23AM  Novogen drug crosses blood-brain barrier AAP
Jun-04-15 08:00AM  Studies Confirm TRXE-009 Crosses the Blood-brain Barrier PR Newswire
Jun-02-15 09:20PM  Novogen Expands Board with Two New Appointments PR Newswire
Jun-01-15 11:47PM  Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of Shortfall PR Newswire
May-27-15 10:02PM  ATM Technology Extended with New Patent Lodgement PR Newswire
May-26-15 06:00PM  Novogen to Present at Brain Tumor Biotech Summit 2015 PR Newswire
May-25-15 08:28PM  Novogen to Present at the 2015 Marcum Microcap Conference PR Newswire
May-17-15 09:08PM  Novogen to Present at Hong Kong Investor Conference PR Newswire
May-13-15 09:39PM  Anisina Confirmed as Effective Anti-Cancer Agent in Animal Studies PR Newswire
May-07-15 06:54PM  Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells PR Newswire
Apr-29-15 03:32AM  Novogen Completes the Private Placement of Equity PR Newswire
Apr-27-15 11:48PM  Novogen Regains Full Compliance with NASDAQ Listing Rule PR Newswire
12:15AM  Novogen Posts Details on Rights Issue Offering for Shareholders PR Newswire
Apr-21-15 10:27PM  Cantrixil Receives Orphan Drug Designation from FDA PR Newswire
11:52AM  Novogen (NVGN) Stock Falls Today on Private Placement at TheStreet
02:41AM  Novogen taps investors for $30.5m Other
Apr-20-15 11:34PM  Novogen Conducts Private Placement and Announces Rights Offering to Shareholders PR Newswire
08:37PM  Novogen poised for capital raising Other
09:00AM  Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer PR Newswire
Apr-17-15 03:12PM  Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration at TheStreet
Apr-16-15 09:43PM  Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer PR Newswire
Apr-09-15 04:22PM  Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results at TheStreet
10:09AM  U.S. stocks turn lower after claims, earnings at MarketWatch
Apr-08-15 11:06PM  Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma PR Newswire
Apr-01-15 10:49PM  Novogen Engages Leading US Investor Relations Firm Other
Mar-30-15 04:52AM  Novogen shares surge on drug data AAP
Mar-29-15 08:53PM  Yale University and Novogen Release Data on Cantrixil Mode of Action Other
Mar-18-15 07:00AM  Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study PR Newswire
Mar-10-15 12:28AM  Sky News, Helen Dalley interviews Dr Graham Kelly PR Newswire
Mar-06-15 03:40AM  Cantrixil Data to be Presented at Two Major Conferences PR Newswire
Mar-04-15 03:28PM  Novogen Makes Big Step In Fighting Brain Cancer at 24/7 Wall St.
08:27AM  Abercrombie drops on sales miss; Wayfair, American Eagle soar at MarketWatch
06:00AM  US Studies Confirm Ability of TRXE-009 to Kill Brain Cancer Stem Cells PR Newswire
Mar-02-15 10:02PM  Novogen to Present at AusBiotech "Broker Meets Biotech" Event PR Newswire
Feb-22-15 09:41PM  Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum PR Newswire
Feb-19-15 03:47PM  Novogen Investor Briefing Well Received Other
Feb-11-15 10:00AM  Novogen Lodges Key Super-benzopyran Patent Other
Feb-03-15 10:00AM  Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015 PR Newswire
Jan-15-15 10:45AM  Novogen Soars 50% Following Brain Stem Cell News Benzinga
Novogen Limited engages in the pharmaceutical research and development business in Australia. The company primarily has two drug technology platforms, which include superbenzopyran (SBPs) and anti-tropomyosin (ATMs). Its SBP technology platform offers Cantrixil, an intra-cavity anti-cancer agent for the treatment of ovarian cancer, malignant ascites, and malignant pleural effusion; and Trilexium for the treatment of brain cancers, neuroblastoma, and melanoma. Its ATM technology platform provides Anisina that destructs cancer cells cytoskeleton. The company is also developing various programs in the areas of regenerative medicine, facioscapulohumeral muscular dystrophy, and lysosomal storage disorder. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.